Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Report Highlights

• The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
  
• Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
  
• Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.

INTRODUCTION

• Examine BCC’s complete catalog of Market Research Reports and place direct orders
• Subscribe to any of BCC’s many industry newsletters
• Read announcements of recently published reports and newly launched newsletters
• Register for BCC’s well-known conferences
• Request additional information on any BCC product
• Take advantage of special offers

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.